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eply
s an organization based in the U.S., the American College of
ardiology recognizes that it has as much to learn as it has to teach
rom our engagements with partners outside the U.S. The goals
nd examples outlined in the letter from Dr. Madu and colleagues
oncerning my recent report (1) are shared ones, and we must work
ollaboratively in order to reach them.
The College’s recent international strategy has been developed
rst and foremost to be collaborative and not prescriptive with
ther international societies and with our international members,
nd second, to work with willing partners to better understand the
eeds that cardiovascular specialists have on a local level to develop
rograms and products that help mitigate those challenges and
mprove the care of all patients with cardiovascular disease. For this
eason, the College has implemented a new international gover-
ance structure aimed at improving international representation
nd exchange. Our primary goals are to provide better value of
embership to our international members, to foster collaboration
round global issues, to improve the care of patients with cardio-
ascular disease, and last, to provide educational and quality
mprovement resources to those wishing to collaborate. We
trongly believe that our strategy of collaboration in both resource-
ich as well as resource-limited settings will help us to achieve our
hared vision of improving quality patient-centered cardiovascular
are globally. I urge you and other international members to
ecome involved in the International Council—which now pro-
ides forums for you to advance initiatives and sustainable struc-
ures to improve world cardiovascular health.
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ole of International
edical Graduates in the
merican College of Cardiology
read with much interest the recent commentary by Dr. W.
ouglas Weaver (1), President of the American College of
ardiology (ACC), in which he addressed the challenges that
nternational medical graduates (IMGs) face when they enter
ellowship programs or clinical practice in the U.S. and proposed
deas to get them more involved and integrated in the functions of
he ACC. Because I am an IMG myself, it was rewarding to see
hat the ACC at its highest leadership level is genuinely interested
n the welfare of IMGs, who certainly go through difficult times to
et into a cardiology fellowship program in the U.S. in the first
lace.
Although most IMGs who complete their cardiovascular train-
ng end up staying in the U.S. in private practice or academic
ositions, a substantial portion do actually go to their countries
mainly developing countries) to start their careers there. Those
lso tend to disconnect from the ACC and, other than attending
he annual ACC or American Heart Association scientific ses-
ions, they are not so much involved in the functions of the college.
any of those IMGs have received rigorous research training in
he U.S. in addition to their clinical training, and unfortunately
heir research productivity significantly decreases once they leave
he U.S. (2). Limited funding, the absence of senior supporting
entors, and the lack of dedicated time all combine to significantly
urtail the research potential of IMGs returning to their develop-
ng countries. How can the ACC support and enhance the
cademic careers of IMGs in their home countries?
First, encourage them to continue their research and to publish
t. There is a feeling, which may be difficult to prove, that there is
certain bias in U.S. and European journals against research
erformed in developing countries. Most of the research conducted
n these countries is clinical rather than basic and although it might
ot be directly relevant to the U.S. health care system, it remains
elevant to “global cardiovascular health.” The ACC could help
MGs by having its journals more “open” to their research or
erhaps having a journal dedicated to cardiovascular health in
eveloping countries just like it has journals dedicated to imaging
r interventions.
Second, help them create a network with leading pharmaceu-
ical companies conducting clinical trials. Most of those companies
iew developing countries primarily as markets for their products,
nd although some of them are beginning to conduct clinical trials
n these countries, their attempts have not been always successful
ecause of the lack of supporting infrastructure and improper
election of sites and investigators. Proper networking among the
CC, pharmaceutical companies, and investigators with solidesearch background can ensure the success of the clinical trials
